Biomedical Research

The aim of this study was to observe the impact of recombinant human endostatin (Endostar) combined with cisplatin (En+Ci) on gastric carcinoma xenografts in nude mice. The nude mice model with gastric carcinoma xenografts was randomly divided into the control group, 0.5 mg/kg En group, 5 mg/kg Ci group, and 5 mg/kg En+5 mg/kg Ci group for the treatment; Microvessel Density (MVD) was performed to detect the expression of CD34, mRNA and protein detection was performed to detect the expression changes of inhibitor of DNA binding 1 (ID1) and Vascular Endothelial Growth Factor (VEGF), and transmission electron microscopy was performed to detect the apoptosis. Compared with the control group, the expressions of ID1, VEGF, and MVD in group En were decreased, the tumor size in group Ci was decreased, and the tumor size in group En+Ci was decreased significantly together with significant apoptosis; the MVD expressions in group En and En+Ci were 11.38 ± 1.25 and 10.93 ± 1.54, respectively, showing no significance (P>0.05). En can inhibit the angiogenesis by reducing the expression of ID1, and promote the apoptosis of tumor cells, thus co-achieving the results of inhibiting the growth and metastasis of tumor, and this can provide a new way of thinking for neoadjuvant chemotherapies of gastric carcinoma.

Author(s): Dinuo Li, Hongzhi Sun, Yubin Wang, Qiang Li, Lei Wang
Abstract | Full-Text | PDF

Share this